Quality of Life in Patients With Generalized Myasthenia Gravis Achieving Sustained Versus Transient Minimal Symptom Expression in the Phase Three Vivacity-MG3 Trial (P9-9.007)

Elena Cortés Vicente; Nolan Campbell; Kavita Gandhi; Marie Fitzgibbon; Ibrahim Turkoz

doi:10.1212/wnl.0000000000213104

June 9, 2026Neurology

Quality of Life in Patients With Generalized Myasthenia Gravis Achieving Sustained Versus Transient Minimal Symptom Expression in the Phase Three Vivacity-MG3 Trial (P9-9.007)

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate treatment response in terms of quality of life for patients achieving different types of minimal symptom expression.
Conducted within the Phase Three Vivacity-MG3 trial framework.
Compared quality of life outcomes between patients with sustained and transient minimal symptom expression.
Patients with sustained minimal symptom expression reported better quality of life.
The treatment response varied significantly between the two groups, highlighting the relevance of achieving sustained symptom management.

Implication

Evaluates quality of life linked to symptom expression in generalized myasthenia gravis, suggesting differences in treatment response.

Abstract

To evaluate minimal symptom expression (MSE) treatment response and quality of life (QoL) in patients achieving sustained vs transient MSE in Vivacity-MG3.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vicente et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f05648c https://doi.org/10.1212/wnl.0000000000213104

View at Publisher

Ask AI

Bookmark

Share

Quality of Life in Patients With Generalized Myasthenia Gravis Achieving Sustained Versus Transient Minimal Symptom Expression in the Phase Three Vivacity-MG3 Trial (P9-9.007)

Key Points

Implication

Abstract

Discussion

Cite This Study

Quality of Life in Patients With Generalized Myasthenia Gravis Achieving Sustained Versus Transient Minimal Symptom Expression in the Phase Three Vivacity-MG3 Trial (P9-9.007)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology